Opioids; require health care professionals to discuss opioid use prior to prescription of Schedule II controlled substances, exceptions provided
Impact
The passage of HB 364 is expected to significantly impact how prescriptions for opioid medications are managed in the state. By introducing mandatory discussions prior to prescribing, the bill seeks to curb the opioid crisis by addressing issues of addiction and overdose head-on. This proactive approach is geared towards enhancing patient safety and informed consent, which could lead to informed decision-making for patients facing acute or chronic pain. Moreover, the bill provides exceptions for patients in specific situations such as cancer treatment, hospice care, and existing treatment for substance abuse, thus recognizing the nuance required in dealing with sensitive healthcare scenarios.
Summary
House Bill 364 mandates that healthcare professionals who have the authority to prescribe opioids engage in discussions with patients regarding the risks and alternatives associated with opioid use before prescribing an initial and a third prescription for Schedule II controlled substances. The intent of this bill is to ensure that patients are well-informed about the potential risks of addiction and overdose, as well as the implications of drug interactions with other substances. By documenting these discussions in the patient's medical records, the bill aims to create a formal accountability structure that reinforces responsible prescribing practices.
Contention
While there is generally strong support for measures aimed at reducing opioid misuse, some points of contention have emerged around HB 364. Supporters advocate for the need to protect patients by ensuring they understand the risks before starting treatment with potent opioids. However, critics express concerns about potential barriers to necessary pain management for patients who genuinely need relief. The requirement for discussions may lead to delays in treatment, especially for those who are in acute pain. Therefore, balancing patient protection with timely access to care remains a crucial debate surrounding the implementation of this legislation.
Stem cell therapy; permitted in certain circumstances, notice and consent requirements provided, exceptions provided, State Board of Medical Examiners required to adopt rules
Controlled substances; regulate sale of nonpsychoactive consumable hemp products by Agriculture Department; require sale of products only in pharmacies; add psychoactive derivatives of hemp as Schedule I drug
Veterinary medicine; veterinarian-client-patient relationship further provided; refilling prescription regulations; relationship shared among a location, provided